WO2003027145A1 - Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire - Google Patents
Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire Download PDFInfo
- Publication number
- WO2003027145A1 WO2003027145A1 PCT/JP2002/009959 JP0209959W WO03027145A1 WO 2003027145 A1 WO2003027145 A1 WO 2003027145A1 JP 0209959 W JP0209959 W JP 0209959W WO 03027145 A1 WO03027145 A1 WO 03027145A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell death
- remedy
- screening
- diseases caused
- cells
- Prior art date
Links
- 230000030833 cell death Effects 0.000 title abstract 7
- 238000012216 screening Methods 0.000 title abstract 6
- 230000034994 death Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 title abstract 2
- 239000000411 inducer Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 101001041365 Homo sapiens Serine protease HTRA2, mitochondrial Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne une nouvelle protéine participant à la mort cellulaire et un gène codant pour cette protéine; l'utilisation de la protéine ou du gène précité afin de cribler un facteur anti-mort cellulaire destiné à traiter des maladies induites par la mort cellulaire excessive ou un médicament destiné à traiter des maladies induites par l'inhibition anormale de la mort cellulaire; et des procédés de criblage. L'invention concerne également HtrA2 humain et des cellules et des animaux exprimant HtrA2 humain permettant de cribler un facteur anti-mort cellulaire destiné à traiter des maladies induites par la mort cellulaire excessive; un procédé de criblage de facteur anti-mort cellulaire destiné à traiter des maladies induites par la mort cellulaire excessive; et un procédé de criblage de médicament permettant de traiter des maladies induites par une inhibition anormale de la mort cellulaire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-294794 | 2001-09-26 | ||
JP2001294794 | 2001-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003027145A1 true WO2003027145A1 (fr) | 2003-04-03 |
Family
ID=19116336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/009959 WO2003027145A1 (fr) | 2001-09-26 | 2002-09-26 | Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003027145A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030256A1 (fr) * | 2003-09-30 | 2005-04-07 | Daiichi Pharmaceutical Co., Ltd. | Inhibition de la mort des cellules nerveuses par inhibition de la degradation de shc3, atf6 ou crebl1 par htra2 et procede d'amelioration des maladies neurodegeneratives |
CN113265387A (zh) * | 2021-01-22 | 2021-08-17 | 中国人民解放军军事科学院军事医学研究院 | 一种成熟HtrA2突变体N196C及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0828003A2 (fr) * | 1996-09-06 | 1998-03-11 | Smithkline Beecham Plc | Sérine protéase humaine |
WO1998050406A1 (fr) * | 1997-05-09 | 1998-11-12 | The General Hospital Corporation | Genes associes a la proliferation cellulaire |
WO1999036550A2 (fr) * | 1998-01-16 | 1999-07-22 | Incyte Pharmaceuticals, Inc. | Molecules de proteases humaines |
-
2002
- 2002-09-26 WO PCT/JP2002/009959 patent/WO2003027145A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0828003A2 (fr) * | 1996-09-06 | 1998-03-11 | Smithkline Beecham Plc | Sérine protéase humaine |
WO1998050406A1 (fr) * | 1997-05-09 | 1998-11-12 | The General Hospital Corporation | Genes associes a la proliferation cellulaire |
WO1999036550A2 (fr) * | 1998-01-16 | 1999-07-22 | Incyte Pharmaceuticals, Inc. | Molecules de proteases humaines |
Non-Patent Citations (9)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030256A1 (fr) * | 2003-09-30 | 2005-04-07 | Daiichi Pharmaceutical Co., Ltd. | Inhibition de la mort des cellules nerveuses par inhibition de la degradation de shc3, atf6 ou crebl1 par htra2 et procede d'amelioration des maladies neurodegeneratives |
CN113265387A (zh) * | 2021-01-22 | 2021-08-17 | 中国人民解放军军事科学院军事医学研究院 | 一种成熟HtrA2突变体N196C及其制备方法和应用 |
CN113265387B (zh) * | 2021-01-22 | 2022-05-20 | 中国人民解放军军事科学院军事医学研究院 | 一种成熟HtrA2突变体N196C及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006092668A3 (fr) | Compositions proteiques de cellules cutanees foetales pour le traitement d'affections, de troubles ou de maladies cutanes et procedes de fabrication et d'utilisation de celles-ci | |
DE60239669D1 (de) | Sojabohnenprotein, verfahren zu seiner herstellung sowie dessen säure enthaltende proteinnahrungsmittel | |
WO2008063382A3 (fr) | Antagonistes de pcsk9 | |
WO2008057457A3 (fr) | Antagonistes de pcsk9 | |
WO2008133647A3 (fr) | Antagonistes de pcsk9 | |
WO2003089619A3 (fr) | Cellules souches placentaires et utilisations | |
AU2003270626A1 (en) | Magnetically modified electrodes as well as methods of making and using the same | |
WO2002015920A3 (fr) | Traitement des maladies d'hyperproliferation | |
WO2005016947A3 (fr) | Modulation antisens de l'expression de la kinase proteine activee par le mitogene p38 | |
AU2003249645A1 (en) | METHODS FOR THE IDENTIFICATION OF IKKAlpha FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES | |
SI1575951T1 (sl) | Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji | |
WO2003097810A3 (fr) | Nitrilases, acides nucleiques les codant et leurs procedes de production et d'utilisation | |
WO2003002108A3 (fr) | Utilisation d'inhibiteurs de tyrosine kinase destines au traitement de maladies inflammatoires | |
DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
WO2004032850A3 (fr) | Utilisations d'antagonistes des zven humaines | |
AU2001251507A1 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
WO2003027145A1 (fr) | Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire | |
WO2001054707A3 (fr) | Utilisation d'au moins un inhibiteur d'aminopeptidase | |
ITRM20030589A1 (it) | Metodo esperto di ricerca, redazione ed edizione di | |
WO2000064422A3 (fr) | Nouveau traitement | |
ATE382620T1 (de) | Pyrano, piperidino, und thiopyrano derivate und methode zur verwendung | |
WO2002062205A3 (fr) | Methodes de diagnostic et de traitement des cardiopathies | |
AU2001256998A1 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
AU2001251508A1 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
WO2003032899A3 (fr) | Procedes et materiaux permettant de cibler et d'affecter des cellules selectionnees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |